Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-509 dose-ranging study in active rheumatoid arthritis on stable DMARD therapy
NL-OMON40008Phase 2Withdrawn
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of decernotinib, sponsored by Vertex Pharmaceuticals. Planned start Mar 2013; status: withdrawn.
02
Drugs
decernotinib
Beyond the preview
Go deeper on NL-OMON40008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40008.